Average cost of drugs for extensively drug-resistant tuberculosis in Pakistan
Pakistan: Average cost of drugs for extensively drug-resistant tuberculosis was 1,923 constant 2022 US$ in 2024. ◆ Volatile
Average cost of drugs for extensively drug-resistant tuberculosis in Pakistan, 2017–2024
Source: WHO (2025) – with minor processing by Our World in Data. Measured in constant 2022 US$.
Analysis
The most recent figure for average cost of drugs for extensively drug-resistant tuberculosis in Pakistan is 1,923 constant 2022 US$, measured in 2024.
The figure is up 299.8% on the previous year and down 82.5% over ten years.
Pakistan ranks 27th of 56 countries on this measure, in the middle of the range.
Average cost of drugs for extensively drug-resistant tuberculosis in Pakistan, year by year
| Year | constant 2022 US$ | Change |
|---|---|---|
| 2017 | 11,000 constant 2022 US$ | — |
| 2018 | 11,000 constant 2022 US$ | +0.0% |
| 2019 | 3,906 constant 2022 US$ | -64.5% |
| 2020 | 3,906 constant 2022 US$ | +0.0% |
| 2021 | 3,905 constant 2022 US$ | -0.0% |
| 2022 | 3,905 constant 2022 US$ | +0.0% |
| 2023 | 481 constant 2022 US$ | -87.7% |
| 2024 | 1,923 constant 2022 US$ | +299.8% |
Pakistan compared with similar countries
- Pakistan's 1,923 constant 2022 US$ is above the median for lower middle income countries, which is 1,525 constant 2022 US$, 1.3× the median. (24 countries reporting)
- Pakistan's 1,923 constant 2022 US$ is below the median for Middle East, North Africa, Afghanistan & Pakistan, which is 2,000 constant 2022 US$, 96% of the median. (7 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 8,635 constant 2022 US$ | 3,906 constant 2022 US$ | 11,000 constant 2022 US$ | 3 |
| 2020s | 2,824 constant 2022 US$ | 481 constant 2022 US$ | 3,906 constant 2022 US$ | 5 |
Countries ranked near Pakistan
More reference data data for Pakistan
- Emission Totals - Indirect emissions (N2O) - Manure applied to Soils 6.05 (2050)
- Emission Totals - Indirect emissions (N2O) - Manure left on Pasture 20.96 (2050)
- Emission Totals - Indirect emissions (N2O) - IPCC Agriculture 61.26 (2050)
- Emission Totals - Indirect emissions (N2O) - Crop Residues 1.98 (2050)
- Emission Totals - Indirect emissions (N2O) - Agricultural Soils 61.26 (2050)
- Emission Totals - Emissions (N2O) - Manure applied to Soils 20.3 (2050)
- Emission Totals - Emissions (N2O) - Manure Management 5.75 (2050)
- Emission Totals - Emissions (N2O) - Manure left on Pasture 91.27 (2050)
- Emission Totals - Emissions (N2O) - IPCC Agriculture 260 (2050)
- Emission Totals - Emissions (N2O) - Crop Residues 10.79 (2050)
Frequently asked questions
- What is average cost of drugs for extensively drug-resistant tuberculosis in Pakistan?
- Average cost of drugs for extensively drug-resistant tuberculosis in Pakistan was 1,923 constant 2022 US$ in 2024, according to WHO (2025) – with minor processing by Our World in Data.
- What is the highest average cost of drugs for extensively drug-resistant tuberculosis recorded in Pakistan?
- The highest recorded value was 11,000 constant 2022 US$ in 2017.
- What is the lowest average cost of drugs for extensively drug-resistant tuberculosis recorded in Pakistan?
- The lowest recorded value was 481 constant 2022 US$ in 2023.
- How does Pakistan rank for average cost of drugs for extensively drug-resistant tuberculosis?
- Pakistan ranks 27th out of 56 countries with data for 2024.
- Is average cost of drugs for extensively drug-resistant tuberculosis rising or falling in Pakistan?
- Over the last ten years it is down 82.5%. The long-run trend across the full record is volatile.
- Where does this Pakistan data come from?
- The figures come from WHO (2025) – with minor processing by Our World in Data, published as part of Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 8 observations, free to reuse under CC BY 4.0 (Our World in Data).
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.